Britannia closes 2003 with several new partnership agreements and significant clinical progress, and aims for strategic partnerships to further develop innovative powder treatment for asthma
Britannia Pharmaceuticals has reported that 2003 was a landmark year for the company, marking significant clinical advancements and strategic partnership development as well as considerable growth in key markets.
Over the course of the year, the company signed three major partnership agreements, made progress in clinical trials for three of its six areas of clinical research, and continued expansion into the United States and other target markets.
"2003 was truly an incredible year for Britannia. "We are thrilled with the progress we have made on all fronts - in our business relationships and in all of our treatment areas," said Max Noble, managing director of Britannia.
"These results are a tribute to the extraordinary commitment of the entire Britannia team to our products, technology and mission.
"One of Britannia's key goals for 2003 was to secure a US partner to further develop and launch our drug addiction treatment, BritLofex, in the United States. "We met this goal when we signed a licensing agreement with US WorldMeds in November.
"Having completed this critical partnership, we will shift our focus in the new year to securing partners for several of our other treatments - most notably, our unique asthma therapy, Pumactant.
"Other out-licensing targets include our treatment for surgical adhesions, our Apomorphine nasal powder for Parkinson's disease, and our dihydroergotamine nasal powder for migraines".
